Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06874335 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Biohaven Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
- 12
- Study locations
NCT06874335: Recruiting Phase 1 study of Solid Tumor, sponsored by Biohaven Therapeutics.
NCT06874335 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Biohaven Therapeutics. The registered enrollment target is 95 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (57% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06874335, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Biohaven Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.
Primary Outcome
Incidence and severity of TEAEs, including DLTs, SAEs and change from baseline for laboratory values, electrocardiograms (ECGs), vital signs, and physical exams to determine the safety profile, MTD, MRAD and RDR of BHV-1530 monotherapy and in combination with cemiplimab.
Conditions Studied
Interventions
- DRUG BHV-1530
Study Locations (12)
Texas
- Site-103 - Austin
- Site-104 - Houston
- Site-101 - Irving
- Site-105 - San Antonio
Colorado
- Site-107 - Denver
Florida
- Site-108 - Lake Mary
Michigan
- Site-110 - Detroit
North Carolina
- Site-115 - Durham
South Carolina
- Site-112 - Myrtle Beach
Tennessee
- Site-116 - Nashville
Utah
- Site-106 - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
What NCT06874335 shows while recruiting
NCT06874335 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which BHV-1530 is the first listed.
NCT06874335 lists 12 locations in 9 states (Texas, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT06874335 about?
NCT06874335 is a clinical study titled "A Phase 1 Study of BHV-1530 in Advanced Solid Tumors". This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.
What is the current status of trial NCT06874335?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2025-03-20. Estimated completion is 2029-03.
What conditions does trial NCT06874335 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06874335?
The interventions under investigation include: BHV-1530 (DRUG).
Who is sponsoring clinical trial NCT06874335?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06874335 being conducted?
This trial has 12 study locations across Colorado, Florida, Michigan, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06874335's enrollment target sits among peer trials
95 91st of 196 higher than 106 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI